Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 13 citations · 29 references
MedicineOncologyPharmacotherapyChemotherapyImmunotherapyOncology PharmacotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaTherapy Response AssessmentBortezomib TherapyLenalidomide TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple MyelomaRelapsed Multiple MyelomaTreatment Cycle Scheduling
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.
29
Modeling Valuations for EuroQol Health States
Paul Dolan · Medical Care · 1997 · 4.6K citations
Interpreting the significance of changes in health-related quality-of-life scores.
David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations
Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 888 citations
Medicine, Hematology, Oncology +16